News Releases

 
News Releases
  Date Title and Summary View
Jan 20, 2017
MOUNTAIN VIEW, Calif., Jan. 20, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI) today announced the presentation of results from its immuno-oncology program at the American Society of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium being held January 19-21, 2017 in San Francisco, California. The presentation highl...
Jan 9, 2017
-- Company Initiates Phase III "ADVOCATE" Clinical Trial for Complement Receptor Inhibitor Avacopan in ANCA Vasculitis; Development Path Outlined in Rare Kidney Disease for Chemokine Receptor Inhibitor ‘CCX140' -- MOUNTAIN VIEW, Calif., Jan. 09, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today provided a corporate upda...
Jan 4, 2017
MOUNTAIN VIEW, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 35th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017 at 12:00 p.m. PT. The conference will be held at the Westin St. Francis Ho...
Dec 22, 2016
- ChemoCentryx to retain commercialization rights in the United States and China, Vifor Pharma gains rights in all other markets - - ChemoC...
Nov 7, 2016
-- Preparing for the Initiation of Phase III Development with Complement 5a Receptor Inhibitor Avacopan (CCX168) for the Treatment of ANCA Vasculitis -- -- Reported Positive Data from Ongoing Pilot Phase II Trial of Avacopan in Patients with Atypical Hemolytic Uremic Syndrome -- -- Highlighted Positive Findings in Complement 3 Glomerulopathy ...
Nov 7, 2016
-- Oral presentation at the American Society of Nephrology (ASN) Kidney Week 2016 to highlight Phase II AAV CLEAR trial results -- -- Oral presentation at the American College of Rheumatology (ACR) 2016 Annual Meeting to highlight Phase II AAV CLASSIC trial results -- MOUNTAIN VIEW, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, In...
Oct 28, 2016
MOUNTAIN VIEW, Calif., Oct. 28, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that the Company's third quarter 2016 financial results will be released after market close on Monday, November 7, 2016. ChemoCentryx executive management will host a conference call beginning at 5:00 p.m. Eastern Time on November 7, 2016, ...
Oct 27, 2016
MOUNTAIN VIEW, Calif., Oct. 27, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that its orally administered complement 5a receptor inhibitor CCX168 (newly designated "avacopan") has shown a beneficial effect on disease in a patient with C3 glomerulopathy (C3G). C3G is a rare disease of the kidney characterized by depo...
Oct 20, 2016
MOUNTAIN VIEW, Calif., Oct. 20, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that effective October 17, 2016, Henry A. McKinnell, Jr, Ph.D., retired chairman and chief executive officer of Pfizer Inc., has been appointed to the Company's Board of Directors. Dr. McKinnell brings significant leadership in operations, ...
Oct 18, 2016
-- CCX872 reduced hepatic inflammation, steatosis, and scarring in models of non-alcoholic steatohepatitis (NASH) -- -- Findings reported at the American College of Gastroenterology (ACG) 2016 Annual Meeting -- MOUNTAIN VIEW, Calif., Oct. 18, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI) today announced the presentation of da...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase